Pfizer Czech Republic - EBIT Growth

Created with Highcharts 6.0.4%200320042005200620072008200920102011201220132014201520162017-200-150-100-50050100150200

Pfizer CR`s EBIT Growth reached 34.8 % in 2017. This is 12017 % less than in the previous year.

$1.99

Buy EBIT Growth data for Pfizer Czech Republic.

$19.99

Buy all data for Pfizer Czech Republic.

from $199/month

Buy annual subscriptions for all our products.

 
CompanyUnit
Amgen Czech Republic %
Bayer Czech Republic %
GlaxoSmithKline Czech Republic %
Merck Czech Republic %
Novartis Czech Republic %
Pfizer Czech Republic %
Roche Czech Republic %
Sanofi-Aventis Czech Republic %
Servier Czech Republic %
Walmark %
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
... ... ... ... ...           56.9 -37.9 11.3 34.9 -15.5    
... ... ...               6.82 -34.6 22.5 8.75 17.7    
... ... ...               31.9 -25.9 -21.8 -29.3 6.70    
... ...                 182 25.3 -41.6 9.10 80.1    
                    1.78 12.9 -2.41 56.3 13.5    
... ...                 114 -79.1 169 -0.115 -42.2    
... ... ...               -39.8 -16.9 165 -26.8 -39.3   ...
... ... ... ...             29.9 -13.9 25.2 -88.8 796    
... ... ... ... ... ... ... ... ... ... ... ... 4.17 0.879 11.5    
... ... ...               34.0 -77.4 -40.2 207 -413